Genetic ablation or pharmacological inhibitors of NLRP3 or ASC and caspase-1 improve glucose tolerance and insulin sensitivity in HFD-fed mice and prevent post-MI cardiac enlargement and limit infarct size [4,68,70,71]. This evidence concerns the gene INS and myocardial infarction.